Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||0.19%||163.53||0.7%||$1333.35m|
|LLY||Eli Lilly & Co.||0.74%||323.99||1.1%||$1075.80m|
|BMY||Bristol-Myers Squibb Co.||-0.01%||70.53||1.0%||$772.67m|
|MRK||Merck & Co., Inc.||0.46%||87.96||0.7%||$713.70m|
|ALNY||Alnylam Pharmaceuticals, Inc.||0.00%||196.79||8.2%||$217.39m|
|ATXI||Avenue Therapeutics, Inc.||41.70%||16.31||0.0%||$197.40m|
|GBT||Global Blood Therapeutics, Inc.||0.00%||68.48||5.4%||$191.16m|
|IDXX||IDEXX Laboratories, Inc.||1.10%||340.39||3.9%||$186.31m|
|HZNP||Horizon Therapeutics Plc||0.00%||64.26||5.4%||$173.65m|
|SRPT||Sarepta Therapeutics, Inc.||0.00%||109.94||12.4%||$136.73m|
Intercept Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline includes OCALIVA, which is used for the treatment of biliary cholangitis, nonalcoholic steatohepatitis, sclerosing cholangitis and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in Morristown, NJ.